Kids News

Today, Dyne Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for zeleciment rostudirsen (z-rostudirsen) for the treatment of individuals living with Duchenne muscular dystrophy who… The post FDA Accepts Dyne Therapeutics’ Biologics License Application for Z-Rostudirsen appeared first on Parent Project Muscular Dystrophy.

Whether you joined us in Orlando or are catching up from home, the learning opportunities from PPMD’s 2026 Annual Conference continue. We’re excited to share that recordings and resources from PPMD’s 2026 Annual Conference are… The post Highlights from PPMD’s 2026 Annual Conference appeared first on Parent Project Muscular Dystrophy.

The FDA has scheduled an Advisory Committee meeting for July 29, 2026 to review Deramiocel, Capricor’s investigational cell therapy for Duchenne muscular dystrophy. The meeting will be held in person with the option to participate… The post Preparing for the Deramiocel FDA Advisory Committee Meeting: How to Submit Written Testimony appeared first on Parent Project Muscular Dystrophy.

Today, Sarepta Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Applications (sNDAs) seeking traditional approval for AMONDYS 45® (casimersen) and VYONDYS 53® (golodirsen). The FDA will… The post FDA Accepts sNDAs to Review Traditional Approval for AMONDYS 45 and VYONDYS 53 appeared first on Parent Project Muscular Dystrophy.

PPMD’s 2026 Annual Conference brought together individuals and families from across the Duchenne and Becker community for three days filled with scientific presentations, discussions around care, clinical trials and quality of life, and of course,… The post Catching Up on PPMD’s 2026 Annual Conference: Part II appeared first on Parent Project Muscular Dystrophy.